Navigation Links
GeoVax's DNA and MVA Vaccines Shipped to HIV Vaccine Trials Network for Use in the Upcoming Phase 2a Trial
Date:10/20/2008

ATLANTA, Oct. 20 /PRNewswire-FirstCall/ -- GeoVax Labs, Inc. (OTC Bulletin Board: GOVX), an Atlanta based biotechnology company, developing human vaccines for diseases caused by HIV-1 (Human Immunodeficiency Virus) and other infectious agents, announced today it has shipped both DNA and MVA components of its AIDS vaccine to the HIV Vaccine Trials Network (HVTN) pharmacy, for use in the upcoming Phase 2a human clinical trial. This Phase 2a study will involve 150 vaccinees and 75 placebo (control) participants. These trials serve as a major milestone, as Phase 2a trials are the most advanced trials to-date for GeoVax.

Dr. Robert McNally, President and CEO of GeoVax Labs Inc., commented, "The shipment of the vaccine to the HIV Vaccine Trials Network is a significant step in preparation for the largest clinical trial yet to be undertaken by GeoVax. Multiple completed Phase 1 safety trials refined the dose and vaccine delivery intervals to optimize the immune responses considered desirable to achieve protection against the HIV-1 virus causing AIDS."

Further, a Biological Master File has been submitted to the Food and Drug Administration (FDA) for review of the manufacturing data for the product shipped to HVTN for use in the Phase 2a trial. The FDA completes its review within four weeks. Upon FDA clearance, HVTN's pharmacy will release GeoVax's DNA and MVA vaccines for its planned Phase 2a trial commencement.

GeoVax AIDS vaccines are designed to prevent development of Acquired Immunodeficiency Disease (AIDS) caused by the virus known as HIV-1 by vaccinating individuals prior to virus infection. The vaccine regimen employs a two component "prime-boost strategy." Trial participants are first administered GeoVax HIV-1 DNA vaccine which "primes" the immune system followed by the second vaccine, GeoVax's HIV-1 MVA (Modified Vaccinia Virus) boost. Both vaccines express the 3 major proteins of the AIDS virus. These proteins mimic more than 50% of the
'/>"/>

SOURCE GeoVax Labs, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Industry Pioneer Joins Profectus BioSciences to Support Innovation in Therapeutic and Preventative Vaccines
2. CDC Immunization Advisory Committee Recommends Two New Pediatric Vaccines from GlaxoSmithKline
3. Iomai, Intercell Chief Scientific Officers to Speak on Future of Vaccines at BIO International Convention Today
4. Nanoemulsion vaccines show increasing promise
5. PharmAthene Closes Acquisition of Avecia Biodefense Vaccines Business Unit
6. PharmAthene Signs Definitive Agreement to Acquire Biodefense Vaccines Business From Avecia
7. Vaccines are Likely to Cause Insulin Dependent Diabetes in Over 2% of Children With a Strong Family History of Insulin Dependent Diabetes, New Data Indicates
8. Emergence of Cancer Vaccines Will Be the Key Factor Driving the Pancreatic Cancer Drug Market to More Than Double by 2016
9. Carrington Subsidiary DelSite Biotechnologies Enters into Technology Evaluation Rights License Agreement for Transdermal Delivery of Vaccines
10. MedImmune Licenses Reverse Genetics Technology to Hungarys Omninvest for Use in Influenza Vaccine Development and Production
11. GeoVax Presents Data at AIDS Vaccine 2008 Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... VA (PRWEB) January 15, 2014 Two ... have continued their sponsorship of an annual competition for ... in, and access to, innovative STEM study. The competition ... TEAMS: Tests of Engineering Aptitude, Mathematics, and Sciences ...
(Date:1/15/2014)... (PRWEB) January 15, 2014 Freeslate, ... solutions, today announced that Lupin Limited, one of India’s ... CM Protégé PharmD System for high throughput ... India, is focused on a wide range of quality, ...
(Date:1/14/2014)... DC (PRWEB) January 14, 2014 Carahsoft ... for Thursday, January 23, 2014 at 2pm EST (11am ... Knowledge.” The topic focuses on how technology can turn ... critical decisions for government agencies. The online webinar will ...
(Date:1/14/2014)... EquitiesIQ, a leading informational research provider, ... is an emerging biomedical company acquiring, developing, manufacturing, and ... , Free report download: http://equitiesiq.com/reports/alliqua/ , In ... team and Board, which launched the company’s new strategy ...
Breaking Biology Technology:Technology Student Association Partners with Leaders in STEM Education Advocacy for Annual Competition 2Technology Student Association Partners with Leaders in STEM Education Advocacy for Annual Competition 3Technology Student Association Partners with Leaders in STEM Education Advocacy for Annual Competition 4Technology Student Association Partners with Leaders in STEM Education Advocacy for Annual Competition 5Lupin Selects Freeslate’s CM Protégé PharmD System to Accelerate Polymorph Screening for Drug Development 2Lupin Selects Freeslate’s CM Protégé PharmD System to Accelerate Polymorph Screening for Drug Development 3Webcast - Natural Language Processing: Converting Raw Data into Actionable Knowledge – Hosted by Carahsoft and CDS Federal Services 2EquitiesIQ Initiates Coverage of Alliqua, Inc. 2EquitiesIQ Initiates Coverage of Alliqua, Inc. 3
... YORK , July 8 Bion Environmental Technologies, ... a public issues forum on July 14 , hosted ... Relations at their Campus Center auditorium.  The forum, sought by ... development group, will address Bion,s proposed beef cattle production facility ...
... Calif. , July 8 ... announced the completion of a Series A financing totaling ... with U.S. Venture Partners, Advanced Technology Ventures, Delphi Ventures ...  The capital will be used to support the company,s ...
... ... interactive healthcare marketing at Digital Pharma West. , ... (PRWEB) -- Viscira™, a leading provider of interactive and ... Return on Interactive” at the Digital Pharma West (DPW) conference last week in San ...
Cached Biology Technology:Bion Confirms Participation in SUNY Oswego's Forum 2Bion Confirms Participation in SUNY Oswego's Forum 3Bion Confirms Participation in SUNY Oswego's Forum 4Calithera Biosciences Closes $40 Million in Series A Financing 2Calithera Biosciences Closes $40 Million in Series A Financing 3Calithera Biosciences Closes $40 Million in Series A Financing 4Viscira Delivers Key Presentation to Pharmaceutical Marketing Professionals at Leading Digital Industry Conference 2
(Date:4/20/2014)... demonstrate a bizarre property never before seen at a ... scientists at the University of Cambridge. The property ... application as wide-ranging as soundproofing, super-absorbent sponges and bulletproof ... if one pulls on an elastic band, the elastic ... squeeze a material and it will expand for ...
(Date:4/20/2014)... used to treat lung, breast and pancreatic cancers also ... the University of California, San Diego School of Medicine ... the surface of drug-resistant tumors that appears responsible for ... of cancer cells. , The findings, published in ... Cell Biology , may point to new therapeutic opportunities ...
(Date:4/20/2014)... with Down syndrome have a heightened risk of developing ... able to explain why. Now, a team of ... the two conditions. , In a study posted online ... researchers track the genetic chain of events that links ... havoc that occurs in ALL. Their findings are ...
Breaking Biology News(10 mins):Bulletproof nuclei? Stem cells exhibit unusual absorption property 2Cancer stem cells linked to drug resistance 2Dana-Farber researchers uncover link between Down syndrome and leukemia 2Dana-Farber researchers uncover link between Down syndrome and leukemia 3
... published by ASM Press educates the reader by focusing ... teaching virology for more than 35 years, Virology: Molecular ... understanding of fundamental virology by emphasizing principles and discussing ... Molecular Biology and Pathogenesis is meant to be used ...
... have found that the hydrodynamic environment of fish can shape ... the Journal of Experimental Biology Web site, was ... Dynamics. Catch a glimpse of a fish,s body shape, ... and mackerel look as if they should outpace frilly reef ...
... Mediterranean Sea has a stable and constant dolphin population off ... also consider the dolphins," says Dr. Aviad Scheinin of the ... commercial fishing endangers dolphin populations in the Mediterranean. This has ... University of Haifa,s Department of Maritime Civilizations. "Unfortunately, we turn ...
Cached Biology News:Virology text focuses on families 2Research finds water movements can shape fish evolution 2Commercial fishing endangers dolphin populations 2Commercial fishing endangers dolphin populations 3
Homo sapiens similar to Cytosolic acyl coenzyme A thioester hydrolase Antigen: Peptide...
Borrelia Burgdorfen (IgG) -Ab EIA Sample Size: 100 l...
96 Well Base Plate...
... ANTI-RNase is a protein ribonuclease inhibitor that noncovalently ... No inhibition is seen with RNase 1, T1, ... distinct from human placental ribonuclease inhibitor in that ... and does not release active RNase in the ...
Biology Products: